View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 26, 2021updated 12 Jul 2022 11:13am

Worldwide Clinical Trials and Trialbee partner to boost enrolment

Worldwide Clinical Trials partners with Trialbee to bolster patient enrolment and streamline timelines for clinical trials.

Worldwide Clinical Trials has partnered with Trialbee to bolster patient enrolment and streamline timelines for clinical trials across the world.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The partnership will integrate worldwide trial infrastructure, therapeutic and recruitment capabilities with technology, real-world data, and nurse call centre qualification.

Worldwide Clinical Trials and Trialbee aim to help trial sponsors better match and recruit eligible participants globally.

Trialbee CEO Matt Walz said: “By combining the global development expertise of Worldwide Clinical Trials with our global patient matching and enrolment platforms, this partnership will lower costs and speed clinical trial timelines with innovative patient matching and enrolment capabilities.”

Identification and retaining of eligible participants are impacted by complex study designs and the need for bigger and diverse patient populations.

More than 50% of regulated trials of small and midsized pharma and biotech companies do not meet their patient recruitment targets, in turn affecting the quality of results and development timelines.

Trial cycle times are also becoming longer due to lowering enrolment and retention associated with changing trends in protocol designs, the companies added.

In Phase II and III trials across all therapeutic areas, 57% and 36% of subjects, respectively, fail to meet screening and randomisation criteria.

Through this collaboration, Worldwide Clinical Trials and Trialbee intend to modify services to cut the drug development cost by matching, enrolling and engaging eligible trial participants across diverse populations globally.

Clients of Worldwide Clinical Trials can now access Trialbee’s data science to improve protocol design and site selection, along with patient identification, recruitment and engagement.

Trialbee Hive provides worldwide access to real-world data and data science to match the most suitable participants and ensure the right population representation.

In August last year, Trialbee partnered with medical data informatics company Clinerion to lower timelines of patient recruitment and enrolment.

In a separate development, Curebase has raised $15m in a Series A funding round to support the development of its decentralised trial software platform and virtual research site capabilities.

The Curebase platform allows patients to participate at home as well as in real-world settings.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena